MACROGENICS, INC. Operating Cash Flow
MACROGENICS, INC. (MGNX) reported Operating Cash Flow of -$76.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- MACROGENICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$40.75M.
- MACROGENICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$35.81M.
- MACROGENICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $43.02M.
- MACROGENICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$30.19M, a 150.17% decline year-over-year.
- MACROGENICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$81.04M.
- MACROGENICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$68.37M.
- MACROGENICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$78.20M.
- MACROGENICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$86.96M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$40.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$76.56M 10-Q · filed 2026-08-14 | -$33.54M derived: sum of 3 quarters · filed 2026-08-14 | -$63.72M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$35.81M 10-Q · filed 2026-05-13 | $7.21M derived: sum of 2 quarters · filed 2026-05-13 | -$22.98M derived: sum of 3 quarters · filed 2026-05-13 | -$69.96M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $43.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $12.84M derived: sum of 2 quarters · filed 2026-03-09 | -$34.15M derived: sum of 3 quarters · filed 2026-08-14 | -$81.04M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$30.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$77.17M derived: sum of 2 quarters · filed 2026-08-14 | -$124.06M 10-Q · filed 2025-11-12 | -$162.47M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$46.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$93.88M 10-Q · filed 2026-08-14 | -$132.28M derived: sum of 3 quarters · filed 2026-08-14 | -$72.12M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$46.89M 10-Q · filed 2026-05-13 | -$85.30M derived: sum of 2 quarters · filed 2026-05-13 | -$25.14M derived: sum of 3 quarters · filed 2026-05-13 | -$69.62M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$38.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $21.75M derived: sum of 2 quarters · filed 2026-03-09 | -$22.73M derived: sum of 3 quarters · filed 2026-03-09 | -$68.37M 10-K · filed 2026-03-09 |
| 2024-09-30 | $60.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $15.68M derived: sum of 2 quarters · filed 2025-11-12 | -$29.97M 10-Q · filed 2025-11-12 | -$58.00M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | -$44.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$90.13M 10-Q · filed 2025-08-14 | -$118.17M derived: sum of 3 quarters · filed 2026-03-09 | -$153.41M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | -$45.64M 10-Q · filed 2025-05-13 | -$73.68M derived: sum of 2 quarters · filed 2026-03-09 | -$108.93M derived: sum of 3 quarters · filed 2026-03-09 | -$111.02M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | -$28.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$63.28M derived: sum of 2 quarters · filed 2026-03-09 | -$65.37M derived: sum of 3 quarters · filed 2026-03-09 | -$78.20M 10-K · filed 2026-03-09 |
| 2023-09-30 | -$35.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$37.34M derived: sum of 2 quarters · filed 2024-11-05 | -$50.17M 10-Q · filed 2024-11-05 | -$20.85M derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-06-30 | -$2.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$14.92M 10-Q · filed 2024-08-06 | $14.40M derived: sum of 3 quarters · filed 2025-03-20 | $4.98M derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-03-31 | -$12.83M 10-Q · filed 2024-05-09 | $16.49M derived: sum of 2 quarters · filed 2025-03-20 | $7.07M derived: sum of 3 quarters · filed 2025-03-20 | -$42.10M derived: sum of 4 quarters · filed 2025-03-20 |
| 2022-12-31 | $29.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $19.90M derived: sum of 2 quarters · filed 2025-03-20 | -$29.26M derived: sum of 3 quarters · filed 2025-03-20 | -$86.96M 10-K · filed 2025-03-20 |
| 2022-09-30 | -$9.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$58.58M derived: sum of 2 quarters · filed 2023-11-06 | -$116.28M 10-Q · filed 2023-11-06 | -$170.59M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | -$49.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$106.86M 10-Q · filed 2023-08-09 | -$161.17M derived: sum of 3 quarters · filed 2024-03-07 | -$175.96M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | -$57.70M 10-Q · filed 2023-05-09 | -$112.00M derived: sum of 2 quarters · filed 2024-03-07 | -$126.80M derived: sum of 3 quarters · filed 2024-03-07 | -$172.49M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | -$54.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$69.10M derived: sum of 2 quarters · filed 2024-03-07 | -$114.79M derived: sum of 3 quarters · filed 2024-03-07 | -$143.83M 10-K · filed 2024-03-07 |
| 2021-09-30 | -$14.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$60.48M derived: sum of 2 quarters · filed 2022-11-03 | -$89.52M 10-Q · filed 2022-11-03 | -$95.05M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | -$45.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$74.73M 10-Q · filed 2022-08-08 | -$80.26M derived: sum of 3 quarters · filed 2023-03-15 | -$105.94M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | -$29.04M 10-Q · filed 2022-05-03 | -$34.57M derived: sum of 2 quarters · filed 2023-03-15 | -$60.25M derived: sum of 3 quarters · filed 2023-03-15 | -$96.79M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | -$5.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$31.21M derived: sum of 2 quarters · filed 2023-03-15 | -$67.76M derived: sum of 3 quarters · filed 2023-03-15 | -$111.90M 10-K · filed 2023-03-15 |
| 2020-09-30 | -$25.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$62.22M derived: sum of 2 quarters · filed 2021-11-02 | -$106.36M 10-Q · filed 2021-11-02 | -$144.41M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$36.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$80.69M 10-Q · filed 2021-07-29 | -$118.73M derived: sum of 3 quarters · filed 2022-02-24 | -$136.12M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$44.14M 10-Q · filed 2021-04-29 | -$82.19M derived: sum of 2 quarters · filed 2022-02-24 | -$99.57M derived: sum of 3 quarters · filed 2022-02-24 | -$148.41M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$38.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$55.43M derived: sum of 2 quarters · filed 2022-02-24 | -$104.27M derived: sum of 3 quarters · filed 2022-02-24 | -$134.27M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$17.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$66.23M derived: sum of 2 quarters · filed 2020-11-04 | -$96.23M 10-Q · filed 2020-11-04 | -$123.45M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$48.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | -$78.84M 10-Q · filed 2020-07-31 | -$106.07M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | -$30.00M 10-Q · filed 2020-05-05 | -$57.23M derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | -$27.23M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$153.23M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | -$126.01M 10-Q · filed 2019-11-06 | |||
| 2017-12-31 | $14.40M 10-K · filed 2020-02-25 | |||
| 2013-12-31 | -$1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-20 | -$14.17M 10-K · filed 2014-03-20 | ||
| 2013-09-30 | -$12.99M 10-Q · filed 2013-11-12 | |||
| 2012-12-31 | $17.70M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-20 | -$6.58M 10-K · filed 2014-03-20 | ||
| 2012-09-30 | -$24.28M 10-Q · filed 2013-11-12 | |||
| 2011-12-31 | $6.76M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |